<div class="infobox infobox-gene">
| | |
|---|---|
| Gene Symbol | TOLLIP |
| Full Name | Toll-Interacting Protein |
| Aliases | IL-1RAcPIP |
| Chromosome | 11p15.5 |
| NCBI Gene ID | [54472](https://www.ncbi.nlm.nih.gov/gene/54472) |
| OMIM | [606277](https://omim.org/entry/606277) |
| Ensembl | [ENSG00000078902](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000078902) |
| UniProt | [Q9H0E2](https://www.uniprot.org/uniprot/Q9H0E2) |
| Associated Diseases | [Alzheimer's disease](/diseases/alzheimers-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), idiopathic pulmonary fibrosis |
</div>
<div class="infobox infobox-gene">
| | |
|---|---|
| Gene Symbol | TOLLIP |
| Full Name | Toll-Interacting Protein |
| Aliases | IL-1RAcPIP |
| Chromosome | 11p15.5 |
| NCBI Gene ID | [54472](https://www.ncbi.nlm.nih.gov/gene/54472) |
| OMIM | [606277](https://omim.org/entry/606277) |
| Ensembl | [ENSG00000078902](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000078902) |
| UniProt | [Q9H0E2](https://www.uniprot.org/uniprot/Q9H0E2) |
| Associated Diseases | [Alzheimer's disease](/diseases/alzheimers-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), idiopathic pulmonary fibrosis |
</div>
TOLLIP encodes Toll-interacting protein, a multifunctional adaptor that negatively regulates Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling while simultaneously functioning as a selective [autophagy](/mechanisms/autophagy-lysosomal-pathway) receptor. TOLLIP bridges innate immune regulation and protein quality control, making it uniquely positioned at the intersection of neuroinflammation and proteostasis — two central pathogenic axes in neurodegeneration. Genetic variants in TOLLIP have been associated with altered susceptibility to [Alzheimer's disease](/diseases/alzheimers-disease) and [ALS](/diseases/amyotrophic-lateral-sclerosis).
TOLLIP spans approximately 52 kb on chromosome 11p15.5 and contains 6 exons. The gene is expressed from a bidirectional promoter responsive to inflammatory stimuli. Expression is upregulated by NF-kappaB signaling, creating a negative feedback loop that limits excessive innate immune activation[@burns2000]. In [microglia](/cell-types/microglia-neuroinflammation), TOLLIP expression is modulated by microglial activation states, with reduced expression in disease-associated microglia (DAM) phenotypes observed in neurodegeneration.
TOLLIP is a critical negative regulator of innate immune signaling. It binds and inhibits IL-1 receptor-associated kinase 1 (IRAK1), preventing its auto-phosphorylation and blocking downstream NF-kappaB and MAPK cascades. TOLLIP attenuates signaling from [TLR2](/genes/tlr2) and [TLR4](/genes/tlr4), key pattern recognition receptors that detect damage-associated molecular patterns (DAMPs) in neurodegeneration, and limits IL-1beta signaling through direct inhibition of the IL-1 receptor signaling complex[@zhang2002].
In the brain, this function is critical because [microglia](/cell-types/microglia) chronically activated by [amyloid-beta](/proteins/amyloid-beta-protein), [alpha-synuclein](/proteins/alpha-synuclein), or [tau](/proteins/tau) DAMPs require TOLLIP to prevent runaway neuroinflammation.
TOLLIP functions as a selective [autophagy](/entities/autophagy) receptor independently of its immune regulatory role. The CUE (Coupling of Ubiquitin to ER degradation) domain recognizes K48- and K63-linked polyubiquitin chains on protein aggregates. TOLLIP contains a functional LIR (LC3-interacting region) motif that recruits autophagosomes to ubiquitinated cargo. It mediates aggrephagy — clearance of polyglutamine-expanded [huntingtin](/proteins/huntingtin) aggregates and other inclusion bodies — and facilitates sorting of ubiquitinated cargo into intraluminal vesicles of multivesicular bodies[@lu2014].
TOLLIP regulates endosomal trafficking through its interaction with Tom1 (target of Myb1), ubiquitin, and phosphatidylinositol-3-phosphate (PI3P). The C2 domain binds PI3P-enriched endosomal membranes, positioning TOLLIP to sort ubiquitinated receptors for lysosomal degradation[@brissoni2006].
TOLLIP variants (rs3750920, rs5743899) have been associated with altered AD susceptibility. TOLLIP deficiency in AD models leads to exacerbated neuroinflammation (loss of TLR/IL-1R negative regulation in response to [amyloid-beta](/proteins/amyloid-beta) DAMPs), impaired aggregate clearance (reduced autophagic degradation of ubiquitinated [tau](/proteins/tau) and Abeta aggregates), and microglial dysfunction (inability to resolve inflammatory responses, shifting toward neurotoxic phenotypes)[@bhatt2017].
TOLLIP expression is reduced in spinal motor [neurons](/entities/neurons) of [ALS](/diseases/amyotrophic-lateral-sclerosis) patients. As a selective autophagy receptor, TOLLIP mediates clearance of ubiquitinated [TDP-43](/proteins/tdp-43-protein) and [SOD1](/proteins/sod1-protein) aggregates. Its depletion impairs aggregate clearance and promotes motor neuron degeneration[@bhatt2019].
TOLLIP participates in clearance of mutant [huntingtin](/proteins/huntingtin-protein) aggregates via aggrephagy. Overexpression of TOLLIP reduces polyglutamine inclusion body formation, while depletion exacerbates aggregation in cellular and animal models[@lu2014].
TOLLIP modulates [alpha-synuclein](/proteins/alpha-synuclein) aggregate clearance and regulates neuroinflammatory responses to extracellular alpha-synuclein fibrils via TLR2 signaling modulation[@kouli2019].
TOLLIP is broadly expressed with brain-relevant patterns: [microglia](/cell-types/microglia) show the highest brain expression (essential for immune homeostasis), [astrocytes](/cell-types/astrocytes) show moderate expression (TLR signaling regulation), neurons show lower expression (primarily autophagy function), and [oligodendrocytes](/cell-types/oligodendrocytes) are also expressed (function in myelin quality control).
Allen Human Brain Atlas: [TOLLIP expression](https://human.brain-map.org/microarray/search/show?search_term=TOLLIP)
Therapeutic strategies targeting TOLLIP include TOLLIP-mimetic peptides designed to enhance IRAK1 inhibition and reduce neuroinflammation, autophagy enhancement strategies to upregulate TOLLIP-mediated aggrephagy for aggregate clearance, AAV-TOLLIP gene therapy to enhance microglial anti-inflammatory capacity, and dual-target approaches exploiting TOLLIP's unique dual role in inflammation and autophagy.
The following diagram shows the key molecular relationships involving TOLLIP — Toll-Interacting Protein discovered through SciDEX knowledge graph analysis: